Slingshot members are tracking this event:
Moleculin Biotech (MBRX) receives approval to begin its second Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia
Slingshot Insights Explained
Jun 20, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Aml, Acute Myeloid Leukemia, Annamycin